EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Overcoming the challenges of cancer drug resistance through bacterial‐mediated therapy

Amin Zargar, Samantha Chang, Ankita Kothari, Antoine M Snijders, Jian-Hua Mao, Jessica Wang, Amanda C Hernández, Jay D Keasling, Trever G Bivona

Chronic Diseases and Translational Medicine · 2019-12 · 5 (4) · 258-266

DOI: 10.1016/j.cdtm.2019.11.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chronic Diseases and Translational Medicine, 2019-12. Verfasst von Amin Zargar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Joint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health Awards.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite tremendous efforts to fight cancer, it remains a major public health problem and a leading cause of death worldwide. With increased knowledge of cancer pathways and improved technological platforms, precision therapeutics that specifically target aberrant cancer pathways have improved patient outcomes. Nevertheless, a primary cause of unsuccessful cancer therapy remains cancer drug resistance. In this review, we summarize the broad classes of resistance to cancer therapy, particularly pharmacokinetics, the tumor microenvironment, and drug resistance mechanisms. Furthermore, we describe how bacterial‐mediated cancer therapy, a bygone mode of treatment, has been revitalized by synthetic biology and is uniquely suited to address the primary resistance mechanisms that confound traditional therapies. Through genetic engineering, we discuss how bacteria can be potent anticancer agents given their tumor targeting potential, anti‐tumor activity, safety, and coordinated delivery of anti‐cancer drugs.

Schlagwörter

Stichwörter der Autor:innen

Bacterial-mediated therapyCancer therapyDrug resistanceSynthetic biology

Autor:innen und Institutionen

  • Joint BioEnergy Institute, Lawrence Berkeley National Laboratory, Emeryville, CA 94608, USA.
  • QB3 Institute, University of California-Berkeley, 174 Stanley Hall, Berkeley, CA 94720, USA.
  • Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
  • Department of Chemical & Biomolecular Engineering, Department of Bioengineering, University of California, Berkeley, CA 94720, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
  • Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94143, USA.

Förderung

  • National Institutes of Health Awards

Zitieren

APA

Zargar, A., Chang, S., Kothari, A., Snijders, A. M., Mao, J. H., Wang, J., Hernández, A. C., Keasling, J. D., & Bivona, T. G. (2019). Overcoming the challenges of cancer drug resistance through bacterial‐mediated therapy. Chronic Diseases and Translational Medicine, 5(4), 258-266. https://doi.org/10.1016/j.cdtm.2019.11.001

Vancouver

Zargar A, Chang S, Kothari A, Snijders AM, Mao JH, Wang J, et al. Overcoming the challenges of cancer drug resistance through bacterial‐mediated therapy. Chronic Diseases and Translational Medicine. 2019;5(4):258-266. doi:10.1016/j.cdtm.2019.11.001

BibTeX
@article{Zargar2019,
  author = {Zargar, Amin and Chang, Samantha and Kothari, Ankita and Snijders, Antoine M and Mao, Jian-Hua and Wang, Jessica and Hernández, Amanda C and Keasling, Jay D and Bivona, Trever G},
  title = {Overcoming the challenges of cancer drug resistance through bacterial‐mediated therapy},
  journal = {Chronic Diseases and Translational Medicine},
  year = {2019},
  volume = {5},
  number = {4},
  pages = {258--266},
  doi = {10.1016/j.cdtm.2019.11.001}
}
Kostenlos starten →